Literature DB >> 24581682

Cholangiocarcinoma.

Nataliya Razumilava1, Gregory J Gores2.   

Abstract

Cholangiocarcinoma represents a diverse group of epithelial cancers united by late diagnosis and poor outcomes. Specific diagnostic and therapeutic approaches are undertaken for cholangiocarcinomas of different anatomical locations (intrahepatic, perihilar, and distal). Mixed hepatocellular cholangiocarcinomas have emerged as a distinct subtype of primary liver cancer. Clinicians need to be aware of intrahepatic cholangiocarcinomas arising in cirrhosis and properly assess liver masses in this setting for cholangiocarcinoma. Management of biliary obstruction is obligatory in perihilar cholangiocarcinoma, and advanced cytological tests such as fluorescence in-situ hybridisation for aneusomy are helpful in the diagnosis. Liver transplantation is a curative option for selected patients with perihilar but not with intrahepatic or distal cholangiocarcinoma. International efforts of clinicians and scientists are helping to identify the genetic drivers of cholangiocarcinoma progression, which will unveil early diagnostic markers and direct development of individualised therapies.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 24581682      PMCID: PMC4069226          DOI: 10.1016/S0140-6736(13)61903-0

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  141 in total

1.  Differentiating mass-forming intrahepatic cholangiocarcinoma from atypical hepatocellular carcinoma using gadoxetic acid-enhanced MRI.

Authors:  Y S Chong; Y K Kim; M W Lee; S H Kim; W J Lee; H C Rhim; S J Lee
Journal:  Clin Radiol       Date:  2012-03-15       Impact factor: 2.350

2.  Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation.

Authors:  K M Boberg; A Bergquist; S Mitchell; A Pares; F Rosina; U Broomé; R Chapman; O Fausa; T Egeland; G Rocca; E Schrumpf
Journal:  Scand J Gastroenterol       Date:  2002-10       Impact factor: 2.423

3.  Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.

Authors:  Juan Valle; Harpreet Wasan; Daniel H Palmer; David Cunningham; Alan Anthoney; Anthony Maraveyas; Srinivasan Madhusudan; Tim Iveson; Sharon Hughes; Stephen P Pereira; Michael Roughton; John Bridgewater
Journal:  N Engl J Med       Date:  2010-04-08       Impact factor: 91.245

4.  Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.

Authors:  Daniela Sia; Yujin Hoshida; Augusto Villanueva; Sasan Roayaie; Joana Ferrer; Barbara Tabak; Judit Peix; Manel Sole; Victoria Tovar; Clara Alsinet; Helena Cornella; Brandy Klotzle; Jian-Bing Fan; Christian Cotsoglou; Swan N Thung; Josep Fuster; Samuel Waxman; Juan Carlos Garcia-Valdecasas; Jordi Bruix; Myron E Schwartz; Rameen Beroukhim; Vincenzo Mazzaferro; Josep M Llovet
Journal:  Gastroenterology       Date:  2013-01-04       Impact factor: 22.682

5.  Jagged1 in the portal vein mesenchyme regulates intrahepatic bile duct development: insights into Alagille syndrome.

Authors:  Jennifer J Hofmann; Ann C Zovein; Huilin Koh; Freddy Radtke; Gerry Weinmaster; M Luisa Iruela-Arispe
Journal:  Development       Date:  2010-12       Impact factor: 6.868

Review 6.  Intrahepatic cholangiocarcinoma: macroscopic type and stage classification.

Authors:  Susumu Yamasaki
Journal:  J Hepatobiliary Pancreat Surg       Date:  2003

7.  Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: A population-based study of U.S. veterans.

Authors:  Hashem B El-Serag; Eric A Engels; Ola Landgren; Elizabeth Chiao; Louise Henderson; Harshinie C Amaratunge; Thomas P Giordano
Journal:  Hepatology       Date:  2009-01       Impact factor: 17.425

Review 8.  Classification, diagnosis, and management of cholangiocarcinoma.

Authors:  Nataliya Razumilava; Gregory J Gores
Journal:  Clin Gastroenterol Hepatol       Date:  2012-09-13       Impact factor: 11.382

9.  An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.

Authors:  Dan Rohle; Janeta Popovici-Muller; Nicolaos Palaskas; Sevin Turcan; Christian Grommes; Carl Campos; Jennifer Tsoi; Owen Clark; Barbara Oldrini; Evangelia Komisopoulou; Kaiko Kunii; Alicia Pedraza; Stefanie Schalm; Lee Silverman; Alexandra Miller; Fang Wang; Hua Yang; Yue Chen; Andrew Kernytsky; Marc K Rosenblum; Wei Liu; Scott A Biller; Shinsan M Su; Cameron W Brennan; Timothy A Chan; Thomas G Graeber; Katharine E Yen; Ingo K Mellinghoff
Journal:  Science       Date:  2013-04-04       Impact factor: 47.728

Review 10.  The challenge of cholangiocarcinoma: dissecting the molecular mechanisms of an insidious cancer.

Authors:  Abigail Zabron; Robert J Edwards; Shahid A Khan
Journal:  Dis Model Mech       Date:  2013-03       Impact factor: 5.758

View more
  541 in total

Review 1.  Cholangiocarcinoma: molecular pathways and therapeutic opportunities.

Authors:  Sumera Rizvi; Mitesh J Borad; Tushar Patel; Gregory J Gores
Journal:  Semin Liver Dis       Date:  2014-11-04       Impact factor: 6.115

2.  Up-regulation of 14-3-3ζ expression in intrahepatic cholangiocarcinoma and its clinical implications.

Authors:  Chi Zhang; Li-Xin Liu; Zhao-Ru Dong; Guo-Ming Shi; Jia-Bin Cai; Peng-Fei Zhang; Ai-Wu Ke; Jing-Xian Yu; Jian Zhou; Jia Fan
Journal:  Tumour Biol       Date:  2014-11-13

3.  Building a staircase to precision medicine for biliary tract cancer.

Authors:  Nataliya Razumilava; Gregory J Gores
Journal:  Nat Genet       Date:  2015-09       Impact factor: 38.330

4.  Genomic spectra of biliary tract cancer.

Authors:  Hiromi Nakamura; Yasuhito Arai; Yasushi Totoki; Tomoki Shirota; Asmaa Elzawahry; Mamoru Kato; Natsuko Hama; Fumie Hosoda; Tomoko Urushidate; Shoko Ohashi; Nobuyoshi Hiraoka; Hidenori Ojima; Kazuaki Shimada; Takuji Okusaka; Tomoo Kosuge; Shinichi Miyagawa; Tatsuhiro Shibata
Journal:  Nat Genet       Date:  2015-08-10       Impact factor: 38.330

5.  miR-24 Inhibition Increases Menin Expression and Decreases Cholangiocarcinoma Proliferation.

Authors:  Laurent Ehrlich; Chad Hall; Julie Venter; David Dostal; Francesca Bernuzzi; Pietro Invernizzi; Fanyin Meng; Jerome P Trzeciakowski; Tianhao Zhou; Holly Standeford; Gianfranco Alpini; Terry C Lairmore; Shannon Glaser
Journal:  Am J Pathol       Date:  2017-01-11       Impact factor: 4.307

6.  Survival Benefits of Surgical Resection in Patients with Recurrent Biliary Tract Carcinoma.

Authors:  Hiroaki Motoyama; Akira Kobayashi; Takahide Yokoyama; Akira Shimizu; Noriyuki Kitagawa; Tsuyoshi Notake; Kentaro Fukushima; Hitoshi Masuo; Takahiro Yoshizawa; Shin-Ichi Miyagawa
Journal:  World J Surg       Date:  2017-11       Impact factor: 3.352

Review 7.  Blood-Bile Barrier: Morphology, Regulation, and Pathophysiology.

Authors:  Tirthadipa Pradhan-Sundd; Satdarshan Pal Monga
Journal:  Gene Expr       Date:  2019-01-15

Review 8.  Fibroblast growth factor receptor 2 fusions as a target for treating cholangiocarcinoma.

Authors:  Mitesh J Borad; Gregory J Gores; Lewis R Roberts
Journal:  Curr Opin Gastroenterol       Date:  2015-05       Impact factor: 3.287

9.  IDH mutations in liver cell plasticity and biliary cancer.

Authors:  Supriya K Saha; Christine A Parachoniak; Nabeel Bardeesy
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

Review 10.  A review of systemic therapy in biliary tract carcinoma.

Authors:  Holger Jansen; Ulrich-Frank Pape; Nalân Utku
Journal:  J Gastrointest Oncol       Date:  2020-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.